Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2023 first-quarter earnings
An illustration of cartoon people in blue shirts looking at blown-up charts

What you need to know about Johnson & Johnson’s 2023 first-quarter earnings

Check out this infographic breakdown of the company’s first-quarter 2023 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Share Article
share to
Inset - Quarterly Earnings Ribbon

This morning, Johnson & Johnson shared its first-quarter performance.

Since its founding in 1886, the company has grown to become the world’s largest, most diversified healthcare products company, with more than 150,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson reported another quarter of strong results across our business in the first quarter of 2023,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “We remain focused on the successful separation of our Consumer Health business and are confident in the long-term growth prospects of our Pharmaceutical and MedTech businesses that continue to drive meaningful value for Johnson & Johnson shareholders.”

For more details about the company’s 2023 first-quarter results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


Q1 2023 earnings infographic

Johnson & Johnson’s 2023 Earnings

Read the earnings press release, which includes full financial details for the first quarter of 2023.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.